J U N E 2 0 1 5 O U T P A T I E N TS U R G E R Y. N E T 2 7
they're actually one of
the least effective tools
we have. Most patients
actually prefer pain to
nausea and vomiting,
both of which are very
common side effects
with opioids. Respiratory
depression is also com-
mon. That's a significant
risk for patients with
sleep apnea, especially
since it's often undiag-
nosed. Constipation is
another common and
unpleasant side effect.
• How serious is the opioid
problem? The United
States is the epicenter of
opioid over-reliance. We
account for about 4% of
the world's population,
yet we consume 90% of
the world's opioids. So
abuse and diversion are
obviously huge concerns,
too. We need to dramati-
cally reduce our reliance
BIGGER. FASTER.
STRONGER.
7335 W. 33
rd
St N. - Wichita, KS 67205 - United States - Phone 316.773.0405 - Fax 316.773.0406 - Phone 877.405.8066 (toll free)
JCBlabs.com
The acquisition of JCB
Laboratories by Fagron
Group,
the global leader in
pharmaceutical
compounding,
is
delivering stunning new
advancements in sterile
compounding
in the U.S.
Introducing Fagron Sterile
Services, the next generation of
compounded
sterile production.
Leading The Industry
Later this year, Fagron
Sterile
Services will open
a
new 503B Human Drug
Outsourcing
Facility utilizing
advanced features never
before
seen in the sterile
compounding industry.
The 50,000-square-foot
lab, among the largest in
the
country, will deliver the
highest level of safety by
combining JCB's experience
and culture of quality along
with
custom robotic equipment,
closed-system
sterile filling
machines,
continuous
monitoring of all areas of
production
and redundant
operating systems.
The next generation of
compounded
sterile production
is here and ready for you.
